Sarah Scagliarini

800 total citations · 1 hit paper
23 papers, 207 citations indexed

About

Sarah Scagliarini is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Sarah Scagliarini has authored 23 papers receiving a total of 207 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Sarah Scagliarini's work include Renal cell carcinoma treatment (8 papers), Prostate Cancer Treatment and Research (8 papers) and Economic and Financial Impacts of Cancer (5 papers). Sarah Scagliarini is often cited by papers focused on Renal cell carcinoma treatment (8 papers), Prostate Cancer Treatment and Research (8 papers) and Economic and Financial Impacts of Cancer (5 papers). Sarah Scagliarini collaborates with scholars based in Italy, Canada and United States. Sarah Scagliarini's co-authors include Antonio Santaniello, Daniela Esposito, Luigi Formisano, Felice Crocetto, Stefania Belli, Alberto Servetto, Fabiana Napolitano, Roberto Bianco, Giuseppe Di Lorenzo and Giacomo Cartenì and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Medicine.

In The Last Decade

Sarah Scagliarini

19 papers receiving 205 citations

Hit Papers

Role of FGFR3 in bladder cancer: Treatment landscape and ... 2023 2026 2024 2025 2023 25 50 75 100
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Role of FGFR3 in bladder cancer: Treatment landscape and future challenges
    2023 101 citations Fabiana Napolitano, Daniela Esposito et al. Cancer Treatment Reviews profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sarah Scagliarini Italy 7 100 98 85 57 41 23 207
Ryo Maruyama Japan 7 65 0.7× 63 0.6× 80 0.9× 19 0.3× 46 1.1× 24 186
Kimiharu Takamatsu Japan 9 58 0.6× 120 1.2× 44 0.5× 31 0.5× 116 2.8× 33 240
Luigi Salzano Italy 6 98 1.0× 211 2.2× 145 1.7× 99 1.7× 37 0.9× 8 272
Gang Zhu China 4 91 0.9× 223 2.3× 189 2.2× 60 1.1× 47 1.1× 9 317
M. Elizabeth H. Hammond United States 8 123 1.2× 155 1.6× 72 0.8× 38 0.7× 114 2.8× 16 307
Kei Daizumoto Japan 8 63 0.6× 79 0.8× 63 0.7× 37 0.6× 38 0.9× 39 195
Giuseppe Tirino Italy 9 108 1.1× 125 1.3× 62 0.7× 75 1.3× 161 3.9× 24 297
Luca Pompella Italy 9 106 1.1× 125 1.3× 60 0.7× 74 1.3× 164 4.0× 25 302
Haowen Jiang China 12 29 0.3× 220 2.2× 55 0.6× 57 1.0× 92 2.2× 20 303
Shigeki Fukusada Japan 10 164 1.6× 134 1.4× 46 0.5× 44 0.8× 98 2.4× 30 265

Countries citing papers authored by Sarah Scagliarini

Since Specialization
Citations

This map shows the geographic impact of Sarah Scagliarini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Scagliarini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Scagliarini more than expected).

Fields of papers citing papers by Sarah Scagliarini

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Scagliarini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Scagliarini. The network helps show where Sarah Scagliarini may publish in the future.

Co-authorship network of co-authors of Sarah Scagliarini

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Scagliarini. A scholar is included among the top collaborators of Sarah Scagliarini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Scagliarini. Sarah Scagliarini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Guida, Annalisa, Alessio Gili, Claudia Mosillo, et al.. (2024). Efficacy and Safety of Pembrolizumab plus Axitinib combination for Metastatic Renal Cell Carcinoma in a Real-World Scenario: Data From the Prospective ProPAXI Study. Clinical Genitourinary Cancer. 22(6). 102225–102225.
3.
Pascale, Maria Rosaria, Flora Ascione, Chiara Di Lorenzo, et al.. (2024). Iron and Heart Failure: Current Concepts and Emerging Pharmacological Paradigms. World Journal of Cardiovascular Diseases. 14(4). 195–216. 1 indexed citations
4.
Napolitano, Fabiana, Daniela Esposito, Alberto Servetto, et al.. (2023). Role of FGFR3 in bladder cancer: Treatment landscape and future challenges. Cancer Treatment Reviews. 115. 102530–102530. 101 indexed citations breakdown →
5.
Napolitano, Fabiana, Annachiara Marra, Felice Crocetto, et al.. (2023). Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors. Cancers. 15(23). 5703–5703.
6.
Romano, Francesco Jacopo, Maria Biglietto, Vincenzo Di Lauro, et al.. (2021). Folinic acid in colorectal cancer: esquire or fellow knight? Real-world results from a mono institutional, retrospective study. Oncotarget. 12(3). 221–229.
7.
Bossi, Paolo, Andrea Antonuzzo, Grazia Armento, et al.. (2021). What to Do and What Not to Do in the Management of Cancer Pain: A Physician Survey and Expert Recommendations. Cancer Management and Research. Volume 13. 5203–5210. 4 indexed citations
8.
Scagliarini, Sarah, et al.. (2019). Incidental finding of non-Hodgkin's lymphoma in a patient affected by castration-sensitive prostate cancer. Medicine. 98(11). e14805–e14805. 2 indexed citations
9.
10.
Masini, Cristina, Maria Giuseppa Vitale, Marco Maruzzo, et al.. (2018). Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study. Clinical Genitourinary Cancer. 17(1). e150–e155. 6 indexed citations
11.
Prisciandaro, Michele, Raffaele Ratta, Francesco Massari, et al.. (2018). Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma. American Journal of Clinical Oncology. 42(1). 42–45. 19 indexed citations
12.
Lorenzo, Giuseppe Di, Guru Sonpavde, Gregory R. Pond, et al.. (2017). Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. European Urology Focus. 4(6). 874–879. 22 indexed citations
13.
Rossetti, Sabrina, Carmine D’Aniello, Gelsomina Iovane, et al.. (2017). Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma. Frontiers in Pharmacology. 8. 484–484. 3 indexed citations
14.
Bosso, Davide, Martina Pagliuca, Guru Sonpavde, et al.. (2017). PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Medicine. 96(24). e6817–e6817. 6 indexed citations
15.
16.
17.
Buonerba, Carlo, Giuseppe Di Lorenzo, Gregory R. Pond, et al.. (2016). Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study. Frontiers in Pharmacology. 7. 487–487. 19 indexed citations
18.
Vitale, Maria Giuseppa, et al.. (2015). Long Progression-free Survival with Afatinib in a Patient with EGFR-unknown Lung Adenocarcinoma after Erlotinib Failure: A Case Report. Tumori Journal. 101(2). e64–e66. 1 indexed citations
19.
Riccardi, Ferdinando, Giuseppe Di Lorenzo, Carlo Buonerba, et al.. (2010). Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer. World Journal of Surgical Oncology. 8(1). 8–8. 2 indexed citations
20.
Lorenzo, Giuseppe Di, et al.. (2009). Targeted Therapy in the Treatment of Metastatic Renal Cell Cancer. Oncology. 77(Suppl. 1). 122–131. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ryo Maruyama Breakdown of academic impact, for papers by Kimiharu Takamatsu Breakdown of academic impact, for papers by Luigi Salzano Breakdown of academic impact, for papers by Gang Zhu Breakdown of academic impact, for papers by M. Elizabeth H. Hammond Breakdown of academic impact, for papers by Kei Daizumoto Breakdown of academic impact, for papers by Giuseppe Tirino Breakdown of academic impact, for papers by Luca Pompella Breakdown of academic impact, for papers by Haowen Jiang Breakdown of academic impact, for papers by Shigeki Fukusada
Rankless by CCL
2026